Kornitzer Capital Management Inc. KS Invests $736,000 in Carlsmed, Inc. $CARL

Kornitzer Capital Management Inc. KS purchased a new stake in shares of Carlsmed, Inc. (NASDAQ:CARL) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 55,000 shares of the company’s stock, valued at approximately $736,000.

Separately, Teacher Retirement System of Texas acquired a new position in Carlsmed in the third quarter worth $2,343,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on CARL shares. Wall Street Zen cut Carlsmed from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Truist Financial restated a “buy” rating and issued a $20.00 price objective (up previously from $18.00) on shares of Carlsmed in a research report on Friday, November 7th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Carlsmed in a research note on Friday, January 9th. BTIG Research reissued a “buy” rating and set a $24.00 price target on shares of Carlsmed in a research note on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (e-)” rating on shares of Carlsmed in a report on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Carlsmed has an average rating of “Moderate Buy” and an average price target of $21.33.

Carlsmed Trading Down 4.6%

Shares of NASDAQ:CARL opened at $12.84 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 12.03 and a quick ratio of 11.91. Carlsmed, Inc. has a 1-year low of $11.45 and a 1-year high of $17.19. The company has a market cap of $341.42 million and a PE ratio of -3.84. The stock’s 50-day moving average price is $13.39.

Carlsmed (NASDAQ:CARL) last issued its earnings results on Thursday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.05.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).